A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis

American Journal of Gastroenterology

Volumn 95, Issue 9, 2000, Pages 2338-2342

  Bharucha, Adil E ^b   Jorgensen, Roberta ^b   Lichtman, S N ^b   LaRusso, N F ^b   Lindor, K D ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYTOKINE; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHOLANGIOGRAPHY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG TOLERANCE; FATIGUE; HEPATOBILIARY DISEASE; HUMAN; PATIENT COMPLIANCE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PRURITUS; SUSTAINED RELEASE PREPARATION;

ADMINISTRATION, ORAL; ADULT; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; BIOLOGICAL MARKERS; BIOPSY; CHOLANGIOGRAPHY; CHOLANGITIS, SCLEROSING; DELAYED-ACTION PREPARATIONS; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; PENTOXIFYLLINE; PILOT PROJECTS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033829920     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(00)01116-3     Document Type: Article

References (27)

1. Primary sclerosing cholangitis
2. Autoantibodies in sclerosing cholangitis against a shared peptide in biliary and colon epithelium
3. Immunohistochemical characterization of hepatic lymphocytes in primary biliary cirrhosis in comparison with primary sclerosing cholangitis and autoimmune chronic active hepatitis
4. Prospective trial of penicillamine in primary sclerosing cholangitis
5. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis
6. Colchicine treatment of primary sclerosing cholangitis
7. Ursodiol for primary sclerosing cholangitis
8. Role of tumor necrosis factor in causing hepatobiliary injury in rats with experimental small bowel bacterial overgrowth
9. Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth
10. Biliary tract disease in rats with experimental small bowel bacterial overgrowth
11. Pentoxifylline prevents fibrosis in an animal model and inhibits platelet-derived growth factor-driven proliferation of fibroblasts
12. Pentoxifylline blocks hepatic stellate cell activation independently of phosphodiesterase inhibitory activity
13. Primary sclerosing cholangitis: Refinement and validation of survival models
14. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)
15. Cytokines and alcoholic liver disease
16. In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease
17. Pentoxifylline in vivo and in vitro down-regulates the expression of the intercellular adhesion molecule-1 in monocytes
18. The effect of alphatocopherol and pentoxyfilline on ischemia-reperfusion induced liver injury in rats
19. Pentoxifylline inhibits growth and collagen synthesis of cultured human hepatic myofibroblast-like cells
20. Effect of pentoxifylline on the degradation of procollagen type I produced by human hepatic stellate cells in response to transforming growth factor-beta 1
21. Pentoxifylline blocks hepatic stellate cell activation independently of phosphodiesterase inhibitory activity
22. Treatment with tumor necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease
23. Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS
24. Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: A prospective, randomized trial
25. Cytokine measurements in septic shock
26. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor a in vitro and in vivo
27. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric antibody (cA2)